(NHC) National HealthCare - NYSE MKT
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE MKT (USA) | Market Cap: 3.148m USD | Total Return: 93.2% in 12m
Avg Turnover: 24.9M
EPS Trend: 83.0%
Rev. Trend: 98.4%
Warnings
No concerns identified
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind
National HealthCare Corporation (NHC), founded in 1971 and headquartered in Murfreesboro, Tennessee, operates a diversified portfolio of senior care and healthcare services through two reporting segments: Inpatient and Homecare and Hospice Services. Its inpatient operations include skilled nursing facilities, assisted living facilities, independent living facilities, specialty medical units (including memory care for Alzheimers patients and sub-acute nursing units), and behavioral health services for adult and geriatric patients with psychiatric or addictive disorders. The homecare and hospice segment provides in-home medical care, hospice and palliative care, pharmacy services, and managed care insurance solutions. NHC also earns ancillary revenue by providing management, accounting, and financial services to third parties and leasing its owned properties to outside operators.
The skilled nursing and senior living industry serves a structurally aging population, with the U.S. Census Bureau projecting that adults aged 65 and over will represent a growing share of the population over the coming decades, supporting long-term demand for these services. Operators in this GICS sub-industry are typically reimbursed through a mix of Medicare and Medicaid (for skilled nursing), private pay, and managed care arrangements, which makes the segment sensitive to government reimbursement policy and labor cost trends.
- Skilled nursing occupancy gains lift Inpatient segment revenue
- Medicare and Medicaid reimbursement rate changes pressure operator margins
- Homecare and Hospice Services expansion outpaces facility-based care
| Net Income: 123.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.20 > 1.0 |
| NWC/Revenue: 12.84% < 20% (prev 15.71%; Δ -2.87% < -1%) |
| CFO/TA 0.14 > 3% & CFO 208.4m > Net Income 123.7m |
| Net Debt (-272.3m) to EBITDA (213.6m): -1.27 < 3 |
| Current Ratio: 1.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.8m) vs 12m ago 1.25% < -2% |
| Gross Margin: 37.21% > 18% (prev 37.73%; Δ -0.52% > 0.5%) |
| Asset Turnover: 99.20% > 50% (prev 88.74%; Δ 10.45% > 0%) |
| Interest Coverage Ratio: 37.07 > 6 (EBIT TTM 168.1m / Interest Expense TTM 4.53m) |
| A: 0.13 (Total Current Assets 449.3m - Total Current Liabilities 253.6m) / Total Assets 1.52b |
| B: 0.56 (Retained Earnings 858.9m / Total Assets 1.52b) |
| C: 0.11 (EBIT TTM 168.1m / Avg Total Assets 1.54b) |
| D: 2.55 (Book Value of Equity 1.09b / Total Liabilities 427.5m) |
| Altman-Z'' = 6.09 = AAA |
| DSRI: 0.87 (Receivables 137.7m/142.2m, Revenue 1.52b/1.37b) |
| GMI: 1.01 (GM 37.73% / 37.21%) |
| AQI: 1.07 (AQ_t 0.24 / AQ_t-1 0.22) |
| SGI: 1.11 (Revenue 1.52b / 1.37b) |
| TATA: -0.06 (NI 123.7m - CFO 208.4m) / TA 1.52b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of June 27, 2026, the stock is trading at USD 206.54 with a total of 503,970 shares traded. Over the past week, the price has changed by +2.49%, over one month by +8.71%, over three months by +28.57% and over the past year by +93.18%.
Current recommended Stop Loss: 197.30 (which is 4.5% or 1.3 ATR below the current price).
National HealthCare has no consensus analysts rating.
| Analysts Target Price | 6.2 | -97% |
P/E Trailing = 25.5749
P/E Forward = 9.8912
P/S = 2.0629
P/B = 2.8854
P/EG = 0.8241
Revenue TTM = 1.52b USD
EBIT TTM = 168.1m USD
EBITDA TTM = 213.6m USD
Long Term Debt = 32.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 26.0m USD (from shortTermDebt, last quarter)
Debt = 39.3m USD (from shortLongTermDebtTotal, last quarter) (leases 39.3m already included)
Net Debt = -272.3m USD (calculated: Debt 39.3m - CCE 311.6m)
Enterprise Value = 2.88b USD (3.15b + Debt 39.3m - CCE 311.6m)
Interest Coverage Ratio = 37.07 (Ebit TTM 168.1m / Interest Expense TTM 4.53m)
EV/FCF = 17.08x (Enterprise Value 2.88b / FCF TTM 168.4m)
FCF Yield = 5.86% (FCF TTM 168.4m / Enterprise Value 2.88b)
FCF Margin = 11.05% (FCF TTM 168.4m / Revenue TTM 1.52b)
Net Margin = 8.11% (Net Income TTM 123.7m / Revenue TTM 1.52b)
Gross Margin = 37.21% ((Revenue TTM 1.52b - Cost of Revenue TTM 957.1m) / Revenue TTM)
Gross Margin QoQ = 30.51% (prev 39.66%)
Tobins Q-Ratio = 1.89 (Enterprise Value 2.88b / Total Assets 1.52b)
Interest Expense / Debt = 11.53% (Interest Expense 4.53m / Debt 39.3m)
Taxrate = 22.69% (37.1m / 163.5m)
NOPAT = 129.9m (EBIT 168.1m * (1 - 22.69%))
Current Ratio = 1.77 (Total Current Assets 449.3m / Total Current Liabilities 253.6m)
Debt / Equity = 0.04 (Debt 39.3m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = -1.27 (Net Debt -272.3m / EBITDA 213.6m)
Debt / FCF = -1.62 (Net Debt -272.3m / FCF TTM 168.4m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.05% (Net Income 123.7m / Total Assets 1.52b)
RoE = 11.68% (Net Income TTM 123.7m / Total Stockholder Equity 1.06b)
RoCE = 15.40% (EBIT 168.1m / Capital Employed (Equity 1.06b + L.T.Debt 32.5m))
RoIC = 8.97% (NOPAT 129.9m / Invested Capital 1.45b)
WACC = 8.26% (E(3.15b)/V(3.19b) * Re(8.25%) + D(39.3m)/V(3.19b) * Rd(11.53%) * (1-Tc(0.23)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 44.72 | Cagr: 2.91%
[DCF] Terminal Value 77.97% ; FCFF base≈137.3m ; Y1≈157.4m ; Y5≈231.6m
[DCF] Fair Price = 240.6 (EV 3.49b - Net Debt -272.3m = Equity 3.76b / Shares 15.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 82.99 | EPS CAGR: 46.67% | SUE: N/A | # QB: 0
Revenue Correlation: 98.38 | Revenue CAGR: 15.19% | SUE: N/A | # QB: 0